Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?
Sorafenib is a tyrosine kinase inhibitor prescribed primarily for the management of metastatic kidney cancer. It exhibits a good safety profile, but is the cause of a number of dermatological adverse effects. The most common and often the most troublesome is a specific hand-foot skin reaction (HFSR) affecting at least 30% of patients. It occurs predominantly on hyperkeratotic areas of the hands and feet that are subject to chronic pressure, suggesting the role played by repeated subclinical traumas in its pathophysiological mechanism. We report here two new cases of sorafenib-induced HFSR, but associated with identical lesions occurring on specific areas of friction (scar, elbows) and suggestive of a Koebner phenomenon. This provides information about the origin of the palmar and plantar lesions observed with sorafenib.
Sibaud
V
V
Department of Dermatology, Institut Claudius Regaud, Centre de Lutte contre le Cancer, 20-24 rue du Pont Saint-Pierre, 31052, Toulouse, France. sibaud.vincent@claudiusregaud.fr
Delord
J P
JP
Chevreau
C
C
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D005533:Foot Dermatoses / Q000139:chemically induced*; D006229:Hand Dermatoses / Q000139:chemically induced*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D012871:Skin Diseases / Q000139:chemically induced; D012882:Skin Tests; D000077157:Sorafenib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib